Статья
Мультифокальный атеросклероз: фокус на профилактике развития ишемических событий
У пациентов, имеющих атеросклеротическое поражение двух и более бассейнов или мультифокальный атеросклероз (МФА), риски ишемических событий крайне высокие. МФА приводит не только к развитию сердечно-сосудистых исходов, но и к снижению качества жизни пациента, уменьшению ее продолжительности, в большинстве случаев — к инвалидизации. Распространенность этой патологии и значимость профилактики неблагоприятных исходов часто недооценивается. В настоящем литературном обзоре рассматривается проблема МФА в контексте ключевых работ по исследованию распространенности, течению многососудистого поражения и снижению риска развития сердечно-сосудистых событий у этой группы пациентов, с акцентом на антиагрегантной и антикоагулянтной терапии.
1. Bhatt DL, Steg PG, Ohman EM, et al.; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-9. doi:10.1001/jama.295.2.180.
2. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317-24. doi:10.1001/jama.286.11.1317.
3. Бокерия Л.А., Голухова Е.З. (ред). Клиническая кардиология: диагностика и лечение. В 3 т. М.: изд-во НЦССХ им. А.Н. Бакулева, 2011 р. 662 с. ISBN: 978-5-7982-0278-2, 978-5-7982-0279-9, 978-5-7982-0280-5.
4. Aboyans V, Ricco JB, Bartelink MEL, et al. Editor’s Choice — 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(3):305-68. doi:10.1016/j.ejvs.2017.07.018.
5. Meizels A, Zeitoun DM, Bataille V, et al.; ALLIANCE investigators on behalf of the working group on Epidemiology of the French Society of Cardiology. Impact of polyvascular disease on baseline characteristics, management and mortality in acute myocardial infarction. The Alliance project. Arch Cardiovasc Dis. 2010;103(4):207-14. doi:10.1016/j.acvd.2010.02.002.
6. Bhatt DL, Peterson ED, Harrington RA, et al.; CRUSADE Investigators. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009;30(10):1195-202. doi:10.1093/eurheartj/ehp099.
7. Meyrier A. Athérosclérose et reins. Nephrol Ther. 2005;1(3):183-202. French. doi:10.1016/j.nephro.2005.06.006.
8. Welten GM, Schouten O, Hoeks SE, et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008;51(16):1588-96. doi:10.1016/j.jacc.2007.11.077.
9. Stojanović SD, Fiedler J, Bauersachs J, et al. Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis. Eur Heart J. 2020;41(31):2983-96. doi:10.1093/eurheartj/ehz919.
10. Beita AKV, Whayne TF. The Superior Mesenteric Artery: From Syndrome in the Young to Vascular Atherosclerosis in the Old. Cardiovasc Hematol Agents Med Chem. 2019;17(2):74-81. doi:10.2174/1871525717666190920100518.
11. Kaasenbrood L, Boekholdt SM, van der Graaf Y, et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation. 2016;134:1419-29. doi:10.1161/CIRCULATIONAHA.116.021314.
12. Cavender MA, Steg PG, Smith SC, et al.; REACH Registry Investigators. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Conti - nued Health (REACH) Registry. Circulation. 2015;132:923-31. doi:10.1161/CIRCULATIONAHA.114.014796.
13. Alberts MJ, Bhatt DL, Mas JL, et al.; REduction of Atherothrombosis for Continued Health Registry Investigators. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J. 2009;30:2318-26. doi:10.1093/eurheartj/ehp355.
14. Subherwal S, Bhatt DL, Li S, et al. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012;5:541-9. doi:10.1161/CIRCOUTCOMES.111.964379.
15. van den Berg MJ, Bhatt DL, Kappelle LJ, et al.; SMART study group; REACH Registry investigators. Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. Eur Heart J. 2017;38(43):3211-8. doi:10.1093/eurheartj/ehx102.
16. Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.
17. Cosentino F, Grant PJ, Aboyans V, et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486.
18. Aboyans V, Ricco JB, Bartelink MEL, et al.; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095.
19. Poredos P, Blinc A, Novo S, et al. How to manage patients with polyvascular atherosclerotic disease. Position paper of the International Union of Angiology. Int Angiol. 2021;40(1):29- 41. doi:10.23736/S0392-9590.20.04518-6.
20. Krempf M, Parhofer KG, Steg PG, et al.; Reach Registry Investigators. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued HealthRegistry). Am J Cardiol. 2010;105(5):667-71. doi:10.1016/j.amjcard.2009.10.048. PMID: 20185014.
21. Bhatt DL, Eagle KA, Ohman EM, et al.; REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350-7. doi:10.1001/jama.2010.1322.
22. Fowkes FG, Low LP, Tuta S, et al.; AGATHA Investigators. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J. 2006;27(15):1861-7. doi:10.1093/eurheartj/ehl114.
23. Барбараш О.Л., Кашталап В.В. Выявление латентного некоронарного атеросклероза у пациентов с острым коронарным синдромом. Есть ли смысл? Комплексные проблемы сердечно-сосудистых заболеваний. 2012;(1):12-6. doi:10.17802/2306-1278-2012-1-12-16.
24. Барбараш Л. С., Шафранская К. С., Иванов С.В. и др. Возможность использования модифицированной шкалы EUROSCORE для оценки годового прогноза коронарного шунтирования у пациентов с мультифокальным атеросклерозом. Патология кровообращения и кардиохирургия. 2010;2:52-6.
25. Kwon H, Kim HK, Kwon SU, et al. Risk of major adverse cardiovascular events in subjects with asymptomatic mild carotid artery stenosis. Sci Rep. 2018;8(1):4700. doi:10.1038/s41598-018-23125-8.
26. Барбараш Л.С., Сумин А.Н., Безденежных А.В. и др. Рас - пространенность мультифокального атеросклероза у больных ишемической болезнью сердца. Комплексные проблемы сердечно-сосудистых заболеваний. 2013;3:4-11.
27. Vlajinac HD, Marinković JM, Maksimović MZ, et al. The prevalence of polyvascular disease in patients with carotid artery disease and peripheral artery disease. Kardiol Pol. 2019;77(10):926-34. doi:10.33963/KP.14945.
28. Vidakovic R, Schouten O, Kuiper R, et al. The prevalence of polyvascular disease in pa - tients referred for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38(4): 435-40. doi:10.1016/j.ejvs.2009.05.006.
29. Cotter G, Cannon CP, McCabe CH, et al.; OPUS-TIMI 16 Investigators. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2003;145(4):622-7. doi:10.1067/mhj.2003.6.
30. Guerrero M, Harjai K, Stone GW, et al. Usefulness of the presence of peripheral vascular disease in predicting mortality in acute myocardial infarction patients treated with primary angioplasty (from the Primary Angioplasty in Myocardial Infarction Database). Am J Cardiol. 2005;96(5):649-54. doi:10.1016/j.amjcard.2005.04.037.
31. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-39. doi:10.1016/s0140-6736(96)09457-3.
32. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med. 2004;164(19):2106-10. doi:10.1001/archinte.164.19.2106.
33. Bonaca MP, Bhatt DL, Cohen M, et al.; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800. doi:10.1056/NEJMoa1500857.
34. Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016;67(23):2719-28. doi:10.1016/j.jacc.2016.03.524.
35. Bhatt DL, Fox KA, Hacke W, et al.; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17. doi:10.1056/NEJMoa060989.
36. Gutierrez JA, Mulder H, Jones WS, et al. Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. JAMA Netw Open. 2018;1(7):e185239. doi:10.1001/jamanetworkopen.2018.5239.
37. Mauri L, Kereiakes DJ, Yeh RW, et al.; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-66. doi:10.1056/NEJMoa1409312.
38. Chan NC, Weitz JI. Antithrombotic Agents. Circ Res. 2019;124(3):426-36. doi:10.1161/CIRCRESAHA.118.313155.
39. Alexander JH, Lopes RD, James S, et al.; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699-708. doi:10.1056/NEJMoa1105819.
40. Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19. doi:10.1056/NEJMoa1112277.
41. Anand SS, Bosch J, Eikelboom JW, et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219-29. doi:10.1016/S0140-6736(17)32409-1.
42. Gutierrez JA, Aday AW, Patel MR, et al. Polyvascular Disease: Reappraisal of the Current Clinical Landscape. Circ Cardiovasc Interv. 2019;12(12):e007385. doi:10.1161/CIRCINTERVENTIONS.119.007385.
43. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020;382(21):1994-2004. doi:10.1056/NEJMoa2000052.
44. Jukema JW, Szarek M, Zijlstra LE, et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;74(9):1167-76. doi:10.1016/j.jacc.2019.03.013.
45. Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. doi:10.1056/NEJMoa1615664.
46. Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338-50. doi:10.1161/CIRCULATIONAHA.117.032235.
47. Bonaca MP, Gutierrez JA, Cannon C, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6(12):934-43. doi:10.1016/S2213-8587(18)30290-0.
48. Gutierrez JA, Scirica BM, Bonaca MP, et al. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). Am J Cardiol. 2019;123(1):145-52. doi:10.1016/j.amjcard.2018.09.014.
49. Verma S, Bhatt DL, Bain SC, et al.; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. Circulation. 2018;137(20):2179-83. doi:10.1161/CIRCULATIONAHA.118.033898.
50. Fujisue K, Tokitsu T, Yamamoto E, et al. Prognostic significance of polyvascular disease in heart failure with preserved left ventricular ejection fraction. Medicine (Baltimore). 2019;98(28):e15959. doi:10.1097/MD.0000000000015959.
51. Weissler EH, Jones WS, Desormais I, et al. Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis. 2020;315:10-7. doi:10.1016/j.atherosclerosis.2020.11.001.